Role of Serine Proteases at the Tumor-Stroma Interface

被引:23
作者
Tagirasa, Ravichandra [1 ]
Yoo, Euna [1 ]
机构
[1] NCI, Biol Chem Lab, Frederick, MD 21701 USA
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
tumor-stromal interaction; serine protease; fibroblast activation protein; urokinase plasminogen activator; kallikrein; granzyme; extracellular matrix remodeling; signaling pathways; FIBROBLAST ACTIVATION PROTEIN; UROKINASE PLASMINOGEN-ACTIVATOR; CANCER-ASSOCIATED FIBROBLASTS; ACTIVITY-BASED PROBES; METASTASIS IN-VIVO; PHASE-II TRIAL; GRANZYME-B; OVARIAN-CANCER; COLON-CANCER; EXTRACELLULAR-MATRIX;
D O I
10.3389/fimmu.2022.832418
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
During tumor development, invasion and metastasis, the intimate interaction between tumor and stroma shapes the tumor microenvironment and dictates the fate of tumor cells. Stromal cells can also influence anti-tumor immunity and response to immunotherapy. Understanding the molecular mechanisms that govern this complex and dynamic interplay, thus is important for cancer diagnosis and therapy. Proteolytic enzymes that are expressed and secreted by both cancer and stromal cells play important roles in modulating tumor-stromal interaction. Among, several serine proteases such as fibroblast activation protein, urokinase-type plasminogen activator, kallikrein-related peptidases, and granzymes have attracted great attention owing to their elevated expression and dysregulated activity in the tumor microenvironment. This review highlights the role of serine proteases that are mainly derived from stromal cells in tumor progression and associated theranostic applications.
引用
收藏
页数:12
相关论文
共 163 条
  • [1] Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer
    Alexopoulou, Dimitra K.
    Papadopoulos, Iordanis N.
    Scorilas, Andreas
    [J]. CLINICAL BIOCHEMISTRY, 2013, 46 (15) : 1453 - 1461
  • [2] PLASMINOGEN-ACTIVATOR INHIBITORS - HORMONALLY REGULATED SERPINS
    ANDREASEN, PA
    GEORG, B
    LUND, LR
    RICCIO, A
    STACEY, SN
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1990, 68 (01) : 1 - 19
  • [3] Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy
    Anh Nguyen
    Ramesh, Anujan
    Kumar, Sahana
    Nandi, Dipika
    Brouillard, Anthony
    Wells, Alexandria
    Pobezinsky, Leonid
    Osborne, Barbara
    Kulkarni, Ashish A.
    [J]. SCIENCE ADVANCES, 2020, 6 (40):
  • [4] Ariga N, 2001, INT J CANCER, V95, P67, DOI 10.1002/1097-0215(20010120)95:1<67::AID-IJC1012>3.0.CO
  • [5] 2-U
  • [6] Structure and biological activity of the extracellular matrix
    Aumailley, M
    Gayraud, B
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 1998, 76 (3-4): : 253 - 265
  • [7] Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
    Baum, Richard P.
    Schuchardt, Christiane
    Singh, Aviral
    Chantadisai, Maythinee
    Robiller, Franz C.
    Zhang, Jingjing
    Mueller, Dirk
    Eismant, Alexander
    Almaguel, Frankis
    Zboralski, Dirk
    Osterkamp, Frank
    Hoehne, Aileen
    Reineke, Ulrich
    Smerling, Christiane
    Kulkarni, Harshad R.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (03) : 415 - 423
  • [8] Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53
    Besch, R.
    Berking, C.
    Kammerbauer, C.
    Degitz, K.
    [J]. CELL DEATH AND DIFFERENTIATION, 2007, 14 (04) : 818 - 829
  • [9] Identification of a new class of nonpeptidic inhibitors of cruzain
    Brak, Katrien
    Doyle, Patricia S.
    McKerrow, James H.
    Ellman, Jonathan A.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (20) : 6404 - 6410
  • [10] Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug
    Brennen, W. Nathaniel
    Rosen, D. Marc
    Wang, Hao
    Isaacs, John T.
    Denmeade, Samuel R.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (17): : 1320 - 1334